临床试验/NCT07093606

NCT07093606招募中不适用

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Sohag University1 个研究点分布在 1 个国家目标入组 100 人开始时间: 2025年7月14日最近更新: 2025年7月30日

干预措施

试验速览

阶段: 不适用
状态: 招募中
发起方: Sohag University
入组人数: 100
试验地点: 1
主要终点: •To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

•Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

研究组 & 干预措施

this group will receive Eltrombopag tabelts

Experimental

ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .

干预措施: Eltrombopag (Drug)

结局指标

主要结局

•To assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

时间窗: 3-6 months after receiving eltombopag

the incidence and severity of liver dysfunction in ITP patients

次要结局

未报告次要终点

研究者

发起方

Sohag University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Peter Adel Alfy

Resident , Internal medicine, Faculty of Medicine Sohag university

Sohag University

研究点 (1)

Loading locations...

相似试验

Unknown

不适用

Hepatotoxicity of Antituberculosis Therapy (HAT) StudyChemical and Drug Induced Liver Injury

NCT04159441Huashan Hospital5,000

Unknown

4 期

Avatrombopag in Patients With End-stage Liver Disease and ThrombocytopeniaDecompensated CirrhosisThrombocytopeniaLiver Failure

NCT04906083Tongji Hospital150

终止

不适用

Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver StiffnessPortal HypertensionLiver Fibroses

NCT03352882University of Pennsylvania1

Unknown

不适用

The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac SurgeryCardiac SurgeryHepatic ImpairmentHeart Failure

NCT02893657Semmelweis University Heart and Vascular Center150

已完成

1 期

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver DysfunctionHepatic ImpairmentHealthy Volunteers

NCT05478603Pfizer24